COMP <GO>

BVS vs DRTS // EV/EBITDA & P/E VALUATION

Bioventus Inc. (Class A) (NASDAQ) VS. Alpha Tau Medical Ltd. (NASDAQ) • 15-METRIC TALLY: BVS 5 — DRTS 0

■ METRIC PARITY

LAST: $14.87 (+1.50%) • MKT CAP: $1.25B

valuation

26.3x

LAST: $13.23 (-0.90%) • MKT CAP: $1.22B

valuation

—

15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BVS VS. DRTS) EMERALD CELL = QUANTITATIVE EDGE

INSTITUTIONAL METRIC	BVS	DRTS	SPREAD (A - B)	ADVANTAGE	DEDICATED URL
Gross Profit Margin	68.30%	—	—	TIE	/gross-margins <GO>
Return on Invested Capital (ROIC)	10.40%	-35.00%	+45.40	BVS	/roic <GO>
EV/EBITDA & P/E Valuation ACTIVE	26.3x	—	—	TIE	/valuation <GO>
Free Cash Flow Yield	5.77%	-2.68%	+8.45	BVS	/fcf-yield <GO>
Operating Margin	9.50%	—	—	TIE	/operating-margins <GO>
Net Profit Margin	4.00%	—	—	TIE	/net-margins <GO>
Revenue Growth (YoY)	-0.90%	—	—	TIE	/revenue-growth <GO>
Dividend Yield & FCF Payout Safety	0.00%	0.00%	0.00	TIE	/dividend-safety <GO>
Altman Z-Score & Debt/Equity	2.25	—	—	TIE	/balance-sheet <GO>
Piotroski F-Score Quality	7/9	2/9	+5.00	BVS	/piotroski-score <GO>
Options Implied Move & Put/Call Skew	—	—	—	TIE	/options-implied-move <GO>
RSI-14 & 200D SMA Momentum	43.9	43.3	+0.67	BVS	/rsi-technicals <GO>
10Y Yield & FRED Macro Beta	—	—	—	TIE	/macro-sensitivity <GO>
Forward P/E Multiple	51.2x	—	—	TIE	/forward-pe <GO>
Enterprise Scale & Market Cap	$1.25B	$1.22B	$27.0M	BVS	/market-cap <GO>

5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY

FISCAL YEAR	BVS REV	DRTS REV	BVS GROSS %	DRTS GROSS %	BVS FCF	DRTS FCF
FY 2025	$568.1M	$0	68.3%	—	$72.1M	-$32.8M
FY 2024	$573.3M	$0	67.7%	—	$37.8M	-$22.0M
FY 2023	$512.3M	$0	—	—	$15.3M	-$18.0M

FRED MACRO REGIME CORRELATION COMPARISON PEARSON r

BVS // BETA —

DRTS // BETA —